Latest Breaking News On - Bionomic clinical advisory board - Page 1 : comparemela.com

Bionomics BNC210 Expansion into Social Anxiety Disorder News provided by Share this article Share this article Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway Pipeline expansion puts Company on path for two Phase 2 programs underway in 2021 ADELAIDE, Australia, May 10, 2021 /PRNewswire/ Bionomics Limited (OTCQB:BNOEF) ( Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) while progressing toward the start of its planned

United statesSouth australiaSuzanne irwinKrista armstrongPrnewswire bionomics limitedClinical development services global head of neuroscienceDrug administrationMerck coU contract research organisationBionomics or companyMerck co incSocial anxiety disorderGeneralised anxiety disorderPost traumatic stress disorderFast trackSocial anxiety